{"id":546444,"title":"Access Consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-11","captureTimestamp":"2026-03-11T03:12:09.359000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/engaging-international-partners/access-statement-vaccine-evidence/consensus-immunobridging-authorizing-new-covid-19-vaccines.html","snippet":"Access Consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines Placebo-controlled disease endpoint trial data are the gold standard for authorizing vaccines. However, for COVID-19 vaccines, it is difficult to conduct efficacy trials in…","rawSnapshotUrl":"/api/snapshots/raw/546444","browseUrl":"https://replay.healtharchive.ca/job-6/20260311031209/https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/engaging-international-partners/access-statement-vaccine-evidence/consensus-immunobridging-authorizing-new-covid-19-vaccines.html#ha_snapshot=546444","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}